Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmon... Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -4.559 | -4.10720720721 | 111 | 112.56 | 104.7 | 13505739 | 108.11969872 | CS |
| 4 | -3.129 | -2.85570867938 | 109.57 | 119.96 | 104.7 | 10746303 | 112.37633793 | CS |
| 12 | 12.511 | 13.3194932396 | 93.93 | 119.96 | 88.57 | 8505607 | 104.03614523 | CS |
| 26 | 22.651 | 27.0330588376 | 83.79 | 119.96 | 81.8298 | 7353395 | 97.31197426 | CS |
| 52 | 33.941 | 46.8151724138 | 72.5 | 119.96 | 62.07 | 7176819 | 84.37038023 | CS |
| 156 | 47.471 | 80.5002543666 | 58.97 | 119.96 | 57.165 | 6917343 | 77.69391309 | CS |
| 260 | 31.311 | 41.6757620125 | 75.13 | 119.96 | 56.56 | 7932630 | 73.31608532 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
